newsfilter
← Latest News
GlobeNewswire·

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular